Searchable abstracts of presentations at key conferences in endocrinology

ea0020p228 | Bone/Calcium | ECE2009

Use of Cinacalcet in patients with intractable primary hyperparathyroidism (PHPT): a UK budget impact analysis

Martin Monique , Robbins Sean , Lu Z John

Introduction: Persistent or intractable PHPT can lead to neuromuscular and psychiatric symptoms and may increase the long-term risk for cardiovascular disease and fractures. Cinacalcet (Mimpara/Sensipar) represents an innovative treatment option for this small group of patients, as it directly acts on the calcium sensing receptors on cell surfaces, reducing the severity of hypercalcemia.Purpose: To estimate the UK budget impact of cinacalcet in patients ...